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Abstract. Human dipeptidyl peptidase III (DPP III) is a member of the zinc-metallopeptidase family M49 
with a role in intracellular protein catabolism. Ligand-free crystal structure of yeast and human ortholo-
gues provided insight into the enzyme's active center and enabled some assumptions about the enzyme - 
substrate interactions. The molecular modeling performed for human and yeast DPP III indicated in-
volvement of Asn406 and Asn415, respectively in ligand binding. To investigate further the role of this 
asparagine residue, conserved in all eukaryotic M49 peptidases, a site-directed mutagenesis of human 
DPP III was carried out. Replacement of Asn406 with Gln, but not with Ser, resulted in a large decrease in 
the enzyme's binding affinity for competitive peptide inhibitor and in catalytic efficiency. Molecular dy-
namics simulations performed for enzyme-substrate complexes, revealed changed coordination of the ac-
tive-site zinc ion and the orientation of the catalytically important His568, in N406Q, but not in the N406S 
complexes.(doi: 10.5562/cca1808) 
Keywords: dipeptidyl peptidase III, molecular dynamics, peptidase family M49, protein structure-
function, site-directed mutagenesis 
 
INTRODUCTION 
Dipeptidyl peptidases (DPPs) cleave dipeptides from the 
(poly)peptides amino termini. In mammalian tissues 
originally four types of dipeptidyl peptidases, DPP I to 
IV have been recognized through hydrolysis of distinct 
synthetic substrates (unsubstituted dipeptidyl 2-
naphthylamides) and extensively characterized.1 Dipep-
tidyl peptidase III (DPP III; EC 3.4.14.4) is a widely-
distributed cytosolic enzyme which selectively hydro-
lyses arginyl-arginyl-2-naphthylamide (Arg2-2NA).2 It 
was at first isolated and biochemically characterized 
from several human (placenta, erythrocytes, seminal 
plasma) and animal (bovine pituitary gland and adrenal 
medulla, porcine spleen, rat and guinea pig brain) tis-
sues3−11 as monomeric acidic metalloexopeptidase (Mr ≈ 
80 000, pI ≈ 4.5) with a broad specificity whose opti-
mally sized substrates are tetra- to octapeptides.5,10 The 
same type of enzyme was partially purified and de-
scribed from two lower eukaryotes, the slime mold 
Dictyostelium discoideum and the yeast Saccharomyces 
cerevisiae.12,13 The physiological substrates of DPP III 
are mostly unknown, although it hydrolyzes a number 
of biologically active peptides in vitro. Besides its con-
tribution in the final steps of intracellular protein cata-
bolism, a regulatory role for DPP III was suggested.5,9 
High concentrations of DPP III in the rat spinal cord and 
its high affinity towards opioid peptides enkephalins 
and endomorphins imply its role in the mammalian 
pain-modulatory system.14,15 Enhanced level of human 
DPP III activity and protein was found in endometrial 
carcinomas and in ovarian malignant neoplasms,16 
moreover correlation of DPP III activity and aggres-
siveness of ovarian primary carcinomas was shown.17 It 
was proposed that DPP III, with several other endogen-
ous peptidases in the lens plays an important role in 
cataractogenesis by inducing lens opacification through 
the intracellular turnover of lens proteins.18 Recently, 
upregulated DPP III was identified as a proteomic bio-
marker for prenatal bisphenol A-exposure in mouse 
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immune organs.19 The first DPP III amino acid se-
quences determined have been rat (738 amino acids) 
and human (737 amino acids), both possessing the cha-
racteristic HELLGH motif that resembles the HExxH 
one present in many metallopeptidases.2,20 Fukasawa et 
al. demonstrated by atomic absorption spectrometry that 
both the recombinant rat DPP III and the natural human 
placental enzyme contain about one Zn2+ ion per mole-
cule.20 The flow of data on complete genome sequences 
in the last decade enabled recognition of dipeptidyl 
peptidase III family (peptidase family M49) as a distinct 
group of metallopeptidases, based on their sequence 
relationships and the unique hexapeptide motif 
HExxGH.21,22 Mutational analysis of rat DPP III has 
confirmed the involvement of two histidines from the 
HELLGH motif (residues 450−455) and Glu508 in 
coordination of the active-site zinc, while for Glu451 it 
was shown to be crucial for the catalytic activity.23 To 
reveal yet unknown constituents of DPP III active site, 
we used bioinformatics to find the amino acid residues 
which are conserved in all M49 family members, and 
site-directed mutagenesis of human DPP III. By such 
combined approach, a functional role for Tyr318 and 
Trp300 was demonstrated in human DPP III.24,25 
In 2008, the gene encoding yeast Saccharomyces 
cerevisiae DPP III was cloned and heterologously ex-
pressed, and the crystal structure of the yeast orthologue 
was solved revealing a novel protein fold – a prototype 
for the whole M49 family.26 DPP III molecule is divided 
into two domains by a cleft containing the catalytic zinc 
ion. The human DPP III 3-D structure recently solved as 
well (PDB code: 3fvy) closely resembles that of the 
yeast protein (PDB code: 3csk). 
Although the crystal structures of yeast and human 
DPPs III (both ligand-free) provided an insight into the 
possible catalytic mechanism, the molecular details on 
substrate recognition by this type of enzyme were missing. 
In our previous study we investigated ligand bind-
ing to human DPP III by combining molecular docking 
and molecular dynamics (MD) simulations, with site-
directed mutagenesis and biochemical experiments.27 
We found that evolutionary conserved His568 is crucial 
for the catalytic efficiency of human DPP III: its substi-
tution with Asn resulted 1300-fold decrease of kcat for 
the Arg2-2NA hydrolysis in respect to the wild-type 
enzyme, and significantly reduced the enzyme affinity 
towards the competitive inhibitor Tyr-Phe-NHOH. Mo-
lecular modeling has indicated that His568 is a constitu-
ent of the S1' subsite (with 7 other amino acid residues) 
and a possible proton donor during hydrolysis. The 
same modeling study pointed out Asn406 as one out of 
3 residues forming the S2 subsite which interacts with a 
ligand P2 residue. In order to check importance of 
Asn406 for the enzymatic activity of the human DPP 
III, we substituted this residue by site-directed mutage-
nesis with Gln and Ser, overexpressed and purified the 
mutated forms and examined their catalytic properties. 
 
EXPERIMENTAL METHODS 
Cloning and Site-directed Mutagenesis 
To obtain DPP III protein with affinity C-terminal six-
histidine tag, full cDNA for DPP III (2.214 kb, con-
tained originally in the clone IRALp962E0242Q2),24 
was cloned into pET-21b vector between NheI and XhoI 
restriction sites according to procedure described earlier 
by Špoljarić et al.25 Thus obtained wild-type expression 
vector was used for further mutagenesis and protein 
expressions. 
Point mutations of the DPP III gene: N406S, and 
N406Q were carried out with the QuikChange II XL 
Site-Directed Mutagenesis kit (Stratagene, USA) by 
using the primers listed in Table 1. The sequencing of 
complete DPP III gene, as well as confirmation of each 
mutant, were obtained with automated sequence ana-
lyzer "ABI PRISM® 3100-Avant Genetic Analyzer" 
(Applied Biosystems, USA) using ABI PRISM BigDye 
Terminator v3.1 Ready Reaction Cycle Sequencing Kit, 
commercial T7 forward and T7 reverse primers, as well 




cgggagaagcttacctttctggagg-3'; DPPIII1614R, 5'- 
ccatgttgagccagttcacgtagatc-3'. All primers were cus-
tom synthesized by Invitrogen (USA). 
 
Heterologous Expression and Purifications of Re-
combinant DPP III Proteins 
Heterologous expression was performed as for human 
DPP III without His6-tag,25 with one modification: after 
induction, cells were grown overnight at 18 °C. 
Table 1. Primers used for site-directed mutagenesis of human DPP III cDNA 
Mutant Nucleotide sequence (5'−3') Primer I Nucleotide sequence (5'−3') Primer II 
N406S gcagacggaaggctttaagtctgtgtcgctgggg ccccagcgacacagacttaaagccttccgtctgc 
N406Q gcagacggaaggctttaagcaggtgtcgctgggg ccccagcgacacctgcttaaagccttccgtctgc 
Codons for the mutated residues are underlined. 
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His6-tagged DPP III proteins were purified by af-
finity chromatography on nickel-nitrilotriacetic acid 
agarose (Ni-NTA Agarose, Qiagen) as already de-
scribed.28 
All fractions of high purity (according to the SDS-
PAGE analysis and the enzymatic activity assayed using 
Arg2-2NA as substrate) were pooled and desalted on 
PD-10 columns (GE Healthcare) equilibrated with 20 
mmol dm−3 Tris-HCl buffer (pH = 7.4). Purified protein 
preparations were stored in 15.6 mmol dm−3 Tris-HCl 
buffer (pH = 7.4) containing 22 % glycerol at −10 °C. 
Protein purity was confirmed by gel electrophore-
sis under denaturing conditions, SDS-PAGE, carried out 
according to the method of Laemmli.29 
Protein concentrations were determined using the 
protein-dye binding assay, with bovine serum albumin 
as a standard.30 
 
Enzyme Activity Assay and Determination of Kinetic 
Parameters 
The enzymatic activities of wild-type and mutant DPP 
III were determined by a standard assay at 37 oC with 
Arg2-2NA as a substrate.31 Kinetic parameters were 
determined at 25 oC and at pH = 8.6, in the presence of 
50 μmol dm−3 CoCl2 by initial rate measurements.25 
Dixon plots were used to determine the Ki values 
for hydroxamate inhibitor at pH = 8.0. 
 
BIOINFORMATIC METHODS 
Similarity Search and Sequence Comparisons 
Sequences of human DPP III homologs from other spe-
cies were obtained by BLAST program search32 from 
UniProt Knowledgebase. Multiple sequence alignment 
was performed using the CLUSTAL W2.33 
 
COMPUTATIONAL METHODS 
System Preparation. 3D structure of the mutants were 
derived from the model based on the crystal structure 
of the ligand-free human DPP III (PDB code: 3fvy).27 
Complexes between the inhibitor Tyr-Phe-NHOH and 
yeast DPP III were built using the crystal structure of 
the C130S yeast DPP III variant (PDB code: 3csk) as a 
template. In the models all Arg and Lys residues are 
positively charged (+1) and all Glu and Asp residues 
are negatively charged (−1), as expected at physiologi-
cal (experimental) conditions. The initial protonation 
of the protein was determined by the program 
WHATIF (with a pH of 7.0), and the protonation of 
histidines was checked according to their ability to 
form hydrogen bonds with neighboring amino acid 
residues. 
Ligands were accommodated into the wild-type 
proteins binding pocket using the combined approach 
consisting of docking by the AutoDock 4 program34 and 
the steered molecular dynamics simulations (for details 
of the procedure see the reference 27). The complexes 
with the mutated proteins were built from the wild-type 
ones by replacing Asn406 either by Gln or Ser. 
The protein parametrization was performed within 
the AMBER ff03 force field of Duan et al.,35 while the 
ligands parameters were derived using Antechamber in 
the Amber10 program package (http://ambermd.org/). 
For the zinc cation, Zn2+, the parameters derived in our 
previous work36 and modified according to a PDB sur-
vey were used.37 
 
Simulations. Simulations of the ligand-free proteins and 
protein-ligand complexes were performed in explicit 
water (TIP3P water type) using periodic boundary con-
ditions. In order to neutralize the system Na+ ions were 
placed at the protein surface, in vicinity of the charged 
amino acid residues. The resulting systems, consisted of 
≈ 80 000 atoms (≈ 23 000 molecules of water). The elec-
trostatic interactions were calculated using the particle-
mesh Ewald method.38,39 
Prior to molecular dynamics simulations, the pro-
tein geometry was optimized in three cycles with differ-
ent constraints. In the first cycle (1500 steps), waters 
and substrate molecule were relaxed, while protein and 
zinc atom were constrained using a harmonic potential 
with a force constant of 133.98 kJ mol−1 Å−2. In the 
second (2500 steps), and the third cycles (1500 steps), 
the same constant was applied to the zinc atom while 
only the protein backbone was constrained with 133.98 
and 41.87 kJ mol−1Å−2, respectively. The energy mini-
mization procedure, consisting of 470 steps of steepest 
descent followed by the conjugate gradient algorithm 
for the remaining optimization steps, was the same in all 
three cycles. During the first period of equilibration (100 
ps of gentle heating from 0 to 300 K), the NVT ensem-
ble was used. The rest of the MD simulations (water 
density adjustment and production simulations) were 
performed at constant temperature and pressure (300 K 
and 1 atm, the NPT ensemble). The temperature was 
held constant using Langevin dynamics with a collision 
frequency of 1 ps−1 and a time step 1 and 2 fs in the case 
of the human, and yeast DPP III, respectively. Bonds 
involving hydrogen atoms were constrained using the 
SHAKE algorithm. The longest were the MD simula-
tions for the DPP III-Arg2-2NA(RRNA) complex (30 
ns), follows simulations for the yeast DPP III-Tyr-Phe-
NHOH(INH) complex (2 × 20 ns), N406Q-RRNA  
(10 ns), N406S-RRNA (5 ns) and N406S-INH (2.5 ns). 
Importantly, the octahedral coordination of the Zn 
cation was retained in all these complexes, except in the 
N406Q-RRNA complex.  
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The root-mean square deviation (RMSD) and root-
mean square coordinate fluctuation (RMSF) of each 
residue in the system were calculated using the "ptraj" 
module of the Amber program. 
 
MM-PBSA Calculations. The binding free energies were 
calculated using the Molecular Mechanics Poisson-
Boltzmann Surface Area (MM-PBSA) approach40 as 
implemented in the AMBER10 program.41,42 MM-
PBSA calculations were performed on the trajectory 
sampled during the last 5 or 2 ns of MD simulations. 
For this purpose snapshots were extracted from the MD 
trajectory every 10 ps and the binding free energies 
were calculated using the equation: 
bind complex protein ligand G G G G        
The Gibbs free energies were approximated with the 
sum of conformational energy and the free energy of 
solvation. The polar component of desolvation free 
energy was calculated using the Poisson-Boltzmann 
method and the non-polar component was determined 
by ΔGnonpol = γSASA + β, in which the solvent-
accessible surface area (SASA) was calculated with the 
MolSurf program.43 The surface tension γ and the offset 
β were set to the standard values of 0.02269 kJ mol−1 
Å−2 and 3.85204 kJ mol−1, respectively. 
 
RESULTS AND DISCUSSION 
Conservation of Asn406 
Molecular modeling pointed out importance of Asn406 in 
human DPP III for the substrate binding.27 To investigate 
the conservation of this asparagine in the metallopepti-
dase M49 family, we performed multiple alignments of 
all M49 family members sequences available in the Uni-
Prot Knowledgebase. Interestingly, it was found that this 
Asn is conserved in all 89 eukaryotic sequences, while all 
of 75 prokaryotic sequences available contained a serine 
residue at this position. Figure 1 illustrates this finding at 
reduced dataset consisting of primary structures from 14 
selected species. Asparagine 406 was located in the 
second, starting from the N-terminus, out of 5 highly 
conserved regions. This result compares well with those 
reported by us in 2004 when altogether only 14 homo-
logous protein sequences − members of the family M49 – 
were deposited in public databases.21 However, up to 
now, there was no experimental evidence on the function 
of the conserved region 2 in proteins of DPP III family. 
 
Expression and Purification of Wild-type and Mu-
tated Human DPP III 
In addition to conservative substitution by glutamine, 
asparagine at position 406 in human DPP III was re-
placed, using the site-directed mutagenesis, also by the 
serine, due to the absolute conservation of this amino 
acid residue in the bacterial sequences (Figure 1). 
Constructs for the His-tagged DPP III, wild-type 
and mutants N406Q and N406S were generated and the 
genes were overexpressed in E. coli BL21(DE3)RIL+ as 
described in the Experimental Methods section. Muta-
tions were confirmed by DNA sequence analysis. The 
wild-type DPP III and mutated forms were purified by 
affinity chromatography on Ni-NTA agarose. Figure 2 
shows the purification profile for N406S. SDS-PAGE 
demonstrated that the wild-type and mutant recombinant 
proteins appeared as bands with similar molecular mass 
of about 82 kDa. 
 
Substrate Specificity towards Dipeptidyl 2-naphthyl-
amides 
Substrate specificity of His-tagged human DPP III and 
its variants was examined with dipeptidyl 2-
naphthylamides (Table 2). Apparently the mutants 
N406Q and N406S similarly to the wild-type enzyme 
preferred Arg2-2NA, while Ala2-2NA was hydrolyzed 
Figure 1. Conservation of Asn406 in eukaryotic sequences of 
family M49. Multiple sequence alignment of a selection of 
significantly similar peptidases of DPP III family (peptidase 
family M49) was obtained using CLUSTAL W2.33 Final 
presentation shows partial alignment diagram of sequences: 
Homo sapiens (Q9NY33), Rattus norvegicus (O55096), Danio 
rerio (Q6DI20), Xenopus laevis (Q6PA12), Drosophila mela-
nogaster (Q9VHR8), Caenorhabditis briggsae (A8XGF7), 
Dictyostelium discoideum (Q557H1), Leishmania major
(Q4QJA6), Giardia lamblia (A8BTV2), Physcomitrella pa-
tens subsp. patens (A9SKT3), Neurospora crassa (Q7SH28), 
Saccharomyces cerevisiae (Q08225), Porphyromonas gingiva-
lis (B2RLB9), and Solibacter usitatus (Q02C27). Residues 
printed in white on black are those identical in at least 12 out 
of 14 aligned proteins, whereas similar amino acid residues 
are shadowed gray. Well conserved Asn is indicated with 
black arrow and the highly conserved sequence region 2 is 
framed. 
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less efficiently (Table 2). This finding is in agreement 
with the published data on native human erythrocyte 
and recombinant untagged human DPP III.25,44 
 
Effect of Metal Ions and Chelating Agent 
Since the Zn2+ ion is natural cofactor of DPPs III, the 
influence of the zinc salt (zinc acetate) addition on the 
activity of all three enzyme variants was investigated. 
Zinc acetate was added in reaction mixture in the con-
centration range of 0.02 μmol dm−3 to 30 μmol dm−3. 
There was no activation observed for any of the en-
zyme forms (wild-type human DPP III, N406S, 
N406Q). On the contrary, already 1 μmol dm−3 
Zn(Ac)2 inhibited all three enzymes about 30 %, and in 
concentration of 30 μmol dm−3 it caused 80 % inhibi-
tion of the wild-type DPP III, and about 95 % inhibi-
tion of both mutants. 
The addition of CoCl2 (5 to 200 μmol dm−3) acti-
vated the wild-type DPP III and both enzyme variants, 
maximal activation (of about 2-fold) being at 50 μmol 
dm−3 CoCl2 for all enzyme forms. 
Effect of metal chelator ethylenediaminetetraacet-
ic acid (EDTA) was examined by preincubation of the 
enzyme with EDTA for 20 min at 23 °C and by follow-
ing the residual activity in function of the chelating 
agent concentration (Figure 3). A very similar inactiva-
tion profile was obtained for all enzyme forms investi-
gated: wild-type human DPP III, wild-type His-tagged 
human DPP III, His-tagged mutants N406S and N406Q. 
Preincubation with already 0.5 mmol dm−3 EDTA sub-
stantially (40−55 %) decreased the enzyme activity 
(Figure 3). 
 
Kinetic Characterization of Asparaginyl Mutants 
Catalytic properties of His-tagged wild-type and aspara-
ginyl mutants of human DPP III were examined using 
favorable synthetic substrate Arg2-2NA, and competi-
tive inhibitor Tyr-Phe-NHOH. Substrate hydrolysis was 
measured at pH 8.6 in the presence of 50 μmol dm−3 
CoCl2. 
The Asn406 with Ser substitution did not change 
significantly Km and kcat for the Arg2-2NA hydrolysis, 
Figure 2. SDS-PAGE (10 % gel) analysis of the purification
progress of human DPP III- His6 protein (N406S mutant) by
affinity chromatography on Ni-NTA agarose column. Lanes:
M - protein molecular mass standards; 1 − E. coli cleared cell
lysate containing recombinant DPP III protein; 2 − flow-
through Ni-NTA column; 3−5 − Ni-NTA column-wash steps
with 20 mmol dm−3 imidazole; 6−9 − human DPP III-His6
protein (N406S mutant) eluted with 150 mmol dm−3 imida-
zole. Proteins were visualized by Coomassie Blue staining. 
Table 2. Substrate specificity towards dipeptidyl 2-naphthyla-
mides 
Substrate 
Relative hydrolysis rate / % 
Wild-type DPP III N406S N406Q 
Arg-Arg-2NA 100 100 100 
Ala-Ala-2NA        1.6        0.9        1.0 
Gly-Pro-2NA     0     0     0 
Gly-Phe-2NA     0     0     0 
The enzymes were incubated at 37 °C in 50 mmol dm−3 Tris-
HCl buffer, pH = 8.0 with 50 μmol dm−3 CoCl2 with the sub-
strates at a final concentration of 0.04 mmol dm−3. 
(100 % = 41.2 μmol or 7.9 μmol or 0.45 μmol of Arg2-2NA 
hydrolyzed per min and milligram of the wild-type DPP III, 
N406S or N406Q, respectively). 
Figure 3. Effect of EDTA on the wild-type (His-tagged and
untagged) and asparaginyl mutants (His-tagged) of recombi-
nant human DPP III. The enzyme was preincubated with
EDTA for 20 min at 23 °C, and the residual activity was de-
termined at 37 °C and at pH 8.6 as described in Experimental
Methods, but without the addition of metal salt (CoCl2). The
enzyme concentrations were: 5.8 × 10−10 mol dm−3 wild-type
without the His-tag, 6.0 × 10−10 mol dm−3 wild-type His-
tagged, 1 × 10−10 mol dm−3 N406S His-tagged, and 6.7 × 10−8
mol dm−3 N406Q His-tagged. The wild-type human DPP III
without the His-tag was purified as described.25 
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neither did Ki for Tyr-Phe-NHOH, compared to the 
wild-type (Table 3). However, large decrease in both the 
binding affinity of the competitive inhibitor (156-fold 
higher Ki value) and in the catalytic efficiency towards 
Arg2-2NA (100-fold smaller ratio kcat/Km, mostly due to 
the decrease in kcat) was observed for the N406Q mutant 
(Table 3). The dissociation constant of Tyr-Phe-NHOH, 
Ki , determined for the wild-type human DPP III-His6 is 
in very good agreement with that determined for the 
wild-type human DPP III without His6-tag.25 The kcat 
value for the hydrolysis of Arg2-2NA of His-tagged 
human DPP III does not differ significantly from the kcat 
of its untagged counterpart (21.8 ± 2.8 s−1), while Km is 
somewhat lower (3.37 μmol dm−3 versus 11.6 μmol 
dm−3).25 Apparently, impaired catalytic efficiency of 
N406Q mutant and its dramatically lowered inhibitor 
binding affinity present experimental evidences of the 
Asn406 importance in human DPP III ligand binding 
and hydrolysis. Since the Km is not a simple enzyme-
substrate binding constant, but represents the dissocia-
tion constants for all enzyme-bound substrate species, it 
is not surprising that the change of Km value does not 
correlate with the inhibitor binding affinity, Ki. Interes-
tingly, the replacement of Asn406 with Ser did not in-
fluence kinetic properties of human DPP III (Table 3). 
Based on the results of the kinetic investigations it 
is evident that the substitution of conserved Asn with 
either Gln or Ser did not change the enzyme preference 
for the synthetic substrates dipeptidyl 2-naphthylamides 
(Table 2). 
The catalytic efficiency reduction induced by the 
N406Q mutation is comparable with that induced by the 
W300L mutation (100-fold versus 78-fold decrease in 
kcat/Km) as shown by us recently.25 However, contribu-
tion of Asn406 to the competitive inhibitor (Tyr-Phe-
NHOH) binding seems to be much more pronounced 
than that of the conserved Trp300, since for W300L the 
Ki was “only” 29-fold higher in comparison with the 
value determined for the wild-type.25 
Enzymatic hydrolysis of Arg2-2NA was measured 
also without the addition of metal activator (CoCl2) to 
the reaction mixture. Again, large decrease in kcat value 
was observed for the N406 mutant only, compared to 
the wild-type His-tagged human DPP III (0.06 s−1 ver-
sus 6.0 s−1), while the Km value was not changed signifi-
cantly (not shown). 
 
MD Simulations of Human DPP III-substrate Com-
plexes 
In order to explain the observed differences in the cata-
lytic properties of two asparaginyl mutants and to un-
derstand better the Asn406 role in ligand binding and in 
the substrate catalysis we performed molecular dynam-
ics simulations for N406S and N406Q mutants ligated 
with Arg-Arg-2NA (RRNA) substrate. Besides a short 
simulation was performed for the complex between the 
N406Q mutant and the Tyr-Phe-NHOH inhibitor. Com-
plexes between RRNA and N406Q and N406S were 
simulated for 10 and 5 ns, respectively, while the 
N406Q - Tyr-Phe-NHOH complex was simulated for 
2.5 ns at room temperature. The simulations resulted 
with an interesting finding on the zinc cation coordina-
tion in the complex with the less active mutant 
(N406Q). While in the N406S mutant, whose activity 
was unchanged compared to the wild-type (Table 3), the 
octahedral coordination of the zinc ion, determined as 
stable in the wild-type DPP III and its complexes,27 was 
preserved during the MD simulations, in the N406Q-
RRNA complex zinc was during MD simulations 
mostly hepta-coordinated (see Figure 4). 
In addition, two hydrogen bonds, between RRNA 
and Glu508 and Ser504, were lost in the N406Q-
substrate complex (Figure 4b). In the N406Q − inhibitor 
complex, the weak van der Waals (v.d.W.) interaction 
with Ser504 was present only during the last 0.5 ns of 
MD simulations, while the CH-π interaction between 
the inhibitor and Ser504 has not been established (Fig-
ure 4d). 
Table 3. Kinetic characterization (means S.E. for three separate determinations) of wild-type human DPP III and Asn406 mu-
tants(a,b) 
Enzyme form Arg-Arg-2NA hydrolysis Tyr-Phe-NHOH 
 Km /µmol dm−3 kcat /s−1 Ki /µmol dm−3 
Wild-type 3.37 ± 1.10 14.13 ± 1.67 0.23 ± 0.03 
N406S 3.99 ± 0.99 10.70 ± 0.92 0.28 ± 0.02 
N406Q 5.03 ± 1.23 0.21 ± 0.02 35.89 ± 5.86 
(a) The kinetic parameters Km and kcat were determined from the initial reaction rates at 25 °C and at pH 8.6 with the Arg-Arg-2NA 
concentrations from 2.5 to 60 μmol dm−3, in the presence of 50 μmol dm−3 CoCl2, using a Hanes plot. 
(b)Ki values were determined with Arg-Arg-2NA as substrate at pH = 8.0, using Dixon plots. 
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Analysis of the overall proteins flexibility showed 
the largest discrepancies in the calculated delta RMSF 
values for residues constituting the protein "lower" 
domain. In the complexes between RRNA and the mu-
tated proteins the "lower" domain region, situated just 
below the enzyme active site, a part of which is mutated 
Asn406, showed increased flexibility, while the rest of 
the domain seemed to be less flexible. In the N406Q-
RRNA complex the beta sheet from the "lower" domain 
(residues 388−408), just below the zinc binding site, 
Figure 4. Coordination of the central zinc ion after: 10 ns of MD simulation for RRNA in complex with a) WT and b) N406Q
mutated human DPP III, 5 ns of MD simulation for c) N406S-RRNA complex, and 2.5 ns of MD simulation for d) N406Q mutant
in complex with Tyr-Phe-NHOH. The zinc cation is shown as a magenta sphere, and ligands are shown in ball and stick represen-
tation. Magenta dashed lines represent zinc coordination with electron donors, and dark blue dashed lines H-bonds that these
electron donors make. 
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slightly moved in the direction of the upper domain. In 
addition, delta RMSF values revealed increased relative 
mobility of the helix connecting the lower and upper 
domain in mutated proteins, as well as increased rigidity 
of the "upper" domain in the N406Q mutant protein 
(Figure 5). 
Another interesting matter noticed in the com-
plexes with the N406Q mutant is orientation of the 
catalytically important His568. Actually, during MD 
simulations His568 is mostly in position to form a hy-
drogen bond with Glu512 and away from Glu508 (not 
shown). Apparently its suggested role in the peptide 
hydrolysis seems to be hindered in the mutant, and this 
is in agreement with the experimental findings. On the 
other hand, according to the MM-PBSA calculations, 
the substrate (RRNA) binding affinities towards the 
wild-type protein and mutants are practically the same, 
with energy difference being within the error of calcula-
tions. 
 
MD Simulation of Yeast DPP III-inhibitor Complexes 
Asn415 in the yeast DPP III corresponds to Asn406 in 
the human DPP III. In order to investigate if this struc-
turally equivalent residue plays a role in the ligand bind-
ing to the yeast orthologue, we performed MD simula-
tions for the yeast DPP III Tyr-Phe-NHOH complexes. 
The inhibitor, Tyr-Phe-NHOH, was accommo-
dated into the active site of the yeast DPP III in two 
different orientations. In one (complex 1) it was bound 
to the Zn ion by the carbonyl oxygen of the first peptide 
bond from the N terminus, and in the other (complex 2) 
by the carbonyl oxygen of the second peptide bond from 
the N terminus. 
In the case of complex 1, Asn415 has v.d.W. in-
teractions with the substrate N terminus, and electro-
static and CH-π interactions with its Tyr (Table 4), 
while in the complex 2, Asn415 interacts with both 
amino acid residues of the inhibitor, Tyr and Phe via 
v.d.W and electrostatic interactions (Table 5). 
The binding free energy evaluated using  
MM-PBSA method was lower for complex 1 (−102.8 ± 
14.1 kJ mol−1), than for complex 2 (−46.1 ± 14.3 kJ 
mol−1). For the inhibitor binding to the human DPP III, 
the evaluated binding free energy was −118.7 ± 21.6 kJ 
mol−1. In this complex inhibitor is bound to the zinc 
cation by the carbonyl oxygen of the second peptide 
bond from the N terminus.27 
Interestingly, MD simulations of human enzyme-
ligand complexes indicated the involvement of Asn406 
in the binding of the residue in P2 position (first Arg 
and Tyr in RRNA and Tyr-Phe-NHOH, respectively) 
only.27 Considering relatively low homology between 
the human and yeast DPP III protein (36 % sequence 
 
Figure 5. The delta RMSF values of the protein backbone (RMSF − <RMSF>) in wild-type and mutant's complexes with synthet-
ic substrate for the last 5 ns and 2 ns of MD simulations, respectively. Flexible loop and α-helix connecting "lower" and "upper"
domain are made by residues 337 to 374. Amino acids 424 to 666 constitute the enzyme's "upper" domain, while rest constitute
the "lower" domain. 
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identity), the different role of Asn415 in the ligand sta-
bilization observed in the yeast complex is not surpris-
ing. 
Different catalytic efficiency (kcat/Km) in the 
RRNA hydrolysis, the human enzyme is two orders 
of magnitude more efficient than the yeast DPP III, 




Recent computational results indicated that asparagine 
residue in position 406 of human dipeptidyl peptidase 
III (737 amino acids) is a constituent of its substrate 
binding subsite S2. 
In order to investigate the functional role of this, 
in all eukaryotic M49 peptidases conserved Asn, expe-
rimentally, we prepared recombinant human DPPs III 
(the wild-type and two mutants, N406S and N406Q), 
heterologously expressed them with C-terminal His6-
tag, purified and kinetically characterized. 
Kinetic results obtained with the N406Q mutant 
support the Asn406 involvement in the ligand (competi-
tive Tyr-Phe-NHOH peptide inhibitor) binding and 
substrate catalysis. However, the substitution of Asn406 
with Ser did not change Km and kcat for the Arg-Arg-
2NA hydrolysis, and Ki for Tyr-Phe-NHOH. 
Molecular dynamics simulations performed for 
complexes between different enzyme forms (wild-type, 
N406S and N406Q) and the substrate Arg-Arg-2NA 
revealed the difference in the active-site zinc coordina-
tion only in the complex with the N406Q mutant. In this 
complex two hydrogen bonds stabilizing the substrate in 
the complex with the wild-type protein were lost, and 
the orientation of catalytically important residue His568 
changed. This could impair ligand binding and catalytic 
efficiency of N406Q enzyme form. 
In yeast DPP III, Asn415 corresponds to Asn406 
in human enzyme. The importance of Asn415 for ligand 
binding was confirmed by MD simulations of yeast DPP 
III-ligand(inhibitor) complexes. 
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